ArticleCase reports in gastrointestinal medicine2020
Ocrelizumab-Induced Severe Colitis.
Article in Case reports in gastrointestinal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Exploring autoimmune endocrine diseases induced by monoclonal antibodies used as multiple sclerosis pharmacotherapy: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Ocrelizumab-induced colitis: VigiBase disproportionality analysis, case reports and literature review.British journal of clinical pharmacology · 2026Review
- Ocrelizumab-induced colitis-critical review and case series from a Romanian cohort of MS patients.Frontiers in neurology · 2025Article
- Localized Colitis Associated With Cholecystectomy in Multiple Sclerosis Patient Treated With Ocrelizumab.Cureus · 2024Article
- Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment.Journal of neurology · 2024Review
- [Comorbidities in multiple sclerosis and their influence on the choice of treatment].Revista de neurologia · 2024Review
- Article
- Two Cases of Acute Diverticulitis Following Ocrelizumab Infusion in Patients With Multiple Sclerosis.Cureus · 2024Article
- Impact of Anti-CD20 therapies on the immune homeostasis of gastrointestinal mucosa and their relationship withFrontiers in pharmacology · 2023Review
- Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis.BMJ case reports · 2022Article
- Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.Human vaccines & immunotherapeutics · 2021Article
- Inflammatory Bowel-Like Disease with Ileocolic and Perianal Involvement Induced by Ocrelizumab: A Case Report.Case reports in gastroenterologyArticle
- Secondary Autoimmune Dermatological Disorders Induced by Multiple Sclerosis Biological Immunotherapy Agents: A Systematic Review of Case Reports.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of severe ocrelizumab (anti-CD20 monoclonal antibody) induced colitis in a 43-year-old woman with multiple sclerosis leading to total colectomy after failing medical therapy. Histology of the colectomy was consistent with medication-induced colitis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.